This finding suggests that IL-2-loaded CAR-T Exos may enhance CD8+ T cell-mediated tumor killing by increasing IL-2 bioavailability in the tumor microenvironment while reducing systemic exposure. The gene discussed is CD8A; the disease is neoplasm.